From the Editor - Pharmaceutical Executive


From the Editor
The industry and its issues, from editor-in-chief William Looney.

Not Enough Science

January 1, 2008

A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?

After the Crash

December 1, 2007

For several decades, pharma got the message that promotion could make consumers want to use new drugs. The system didn't work with Pfizer's Exubera. That's surprising news, but is it bad news?

Chasing Perfection

November 1, 2007

A hospital safety expert says it's now possible to completely eliminate certain adverse events. Pharma can't claim the same yet, but is it time for us to start imagining a time when we can "benchmark perfection"?

Are We Safer Yet?

October 1, 2007

FDA has just premiered a new newsletter on drug safety. There's just one little problem....

What Do You Say?

September 1, 2007

In this issue, a longtime contributor to this magazine, former FDA official, and generally thoughtful, knowledgeable person concludes his excellent three-part series on drug safety with a look at how risk is communicated to patients and doctors. It's a fine, detailed, subtle piece of work, and I recommend it to you. (See "Failure to Communicate".)

The Price is Wrong

July 30, 2007

Of all pharma's marketing tactics, the hardest to swallow was "marketing the spread." This was a scheme developed in the 1990s for physician-administered drugs (PADs)—injectables, cancer drugs, etc., which are purchased from wholesalers by physicians and reimbursed by Medicare or third-party payers. Until recently, reimbursement was based on Average Wholesale Price (AWP). This sounds like it ought to mean the average of prices paid to wholesalers, but in practice, it was always closer to sticker price. Manufacturers discovered that they could give physicians a tidy bonus by creating a spread between AWP and what docs paid.


July 3, 2007

The Acomplia story isn't ending. It's just beginning. Get ready to see what happens when a much-desired drug is marketed by people accountable to no one.

From the Editor: Not His Problem

June 1, 2007

It's not FDA's job to make doctors and patients take more responsibility for using drugs wisely. But whose job is it? Really, whose?

From the Editor: Incurable

March 1, 2007

There are good reasons why we shouldn't permit lifestyle drugs on the market. But as a society, we've already shown that those reasons don't mean much to us.


Click here